At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 218 enrolled
Drug / intervention
Luminate 1.0mg +4 moredrug
Likely dose
Luminate 1.0mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Randomized, Controlled, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of Luminate® (ALG-1001) as Compared to Avastin® in the Treatment of Diabetic Macular Edema (DME)
In Brief
A Phase 2 clinical trial evaluating Luminate 1.0mg, Luminate 2.0mg, and 3 other interventions for Diabetic Macular Edema. Completed, enrolled 218 participants across 17 sites.
Detailed Summary
A Phase 2 Multi center, Randomized, Controlled, Double-Masked Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of Luminate® (Alg-1001) As Compared To Avastin® In The Treatment Of Diabetic Macular Edema
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema
CountriesUnited States
CollaboratorsTrial Runners, LLC, Duke University
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartOct 2014
First PostedJan 2015
Primary CompletionMay 2017
Study CompletionJun 2017
TodayJul 2026
First PostedJan 28, 2015
Enrollment StartOct 13, 2014
Primary CompletionMay 16, 2017
Study CompletionJun 13, 2017
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.4 years ago
Interventions
Luminate 1.0mgdrug
Luminate 2.0mgdrug
Luminate 3.0mgdrug
Avastindrug
Luminate 0.5mgdrug